Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition.

Köster F, Engel JB, Schally AV, Hönig A, Schröer A, Seitz S, Hohla F, Ortmann O, Diedrich K, Buchholz S.

Breast Cancer Res Treat. 2009 Jul;116(2):273-9. doi: 10.1007/s10549-008-0120-4. Epub 2008 Jul 16.

PMID:
18629632
2.

Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer.

Schally AV, Varga JL, Engel JB.

Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):33-43. Review.

PMID:
18084344
3.

Endocrine and antineoplastic actions of growth hormone-releasing hormone antagonists.

Kovács M, Schally AV, Varga JL, Zarándi M.

Curr Med Chem. 2008;15(4):314-21. Review.

PMID:
18288987
4.

Extrapituitary effects of the growth hormone-releasing hormone.

Kiaris H, Schally AV, Kalofoutis A.

Vitam Horm. 2005;70:1-24. Review.

PMID:
15727800
5.

New treatment approaches for prostate cancer based on peptide analogues.

Stangelberger A, Schally AV, Djavan B.

Eur Urol. 2008 May;53(5):890-900. doi: 10.1016/j.eururo.2007.12.021. Epub 2007 Dec 26. Review.

PMID:
18201818
6.

Pharmacotherapy of triple-negative breast cancer.

Arslan C, Dizdar O, Altundag K.

Expert Opin Pharmacother. 2009 Sep;10(13):2081-93. doi: 10.1517/14656560903117309. Review.

PMID:
19640211
7.

Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.

Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. Review.

8.

Antagonists of growth hormone-releasing hormone in oncology.

Schally AV, Varga JL.

Comb Chem High Throughput Screen. 2006 Mar;9(3):163-70. Review.

PMID:
16533148
9.

Growth hormone-releasing hormone and extra-pituitary tumorigenesis: therapeutic and diagnostic applications of growth hormone-releasing hormone antagonists.

Kiaris H, Koutsilieris M, Kalofoutis A, Schally AV.

Expert Opin Investig Drugs. 2003 Aug;12(8):1385-94. Review.

PMID:
12882623
10.

What is triple-negative breast cancer?

Irvin WJ Jr, Carey LA.

Eur J Cancer. 2008 Dec;44(18):2799-805. doi: 10.1016/j.ejca.2008.09.034. Epub 2008 Nov 12. Review.

PMID:
19008097
11.
12.

New approaches to the therapy of various tumors based on peptide analogues.

Schally AV.

Horm Metab Res. 2008 May;40(5):315-22. doi: 10.1055/s-2008-1073142. Review.

PMID:
18491250
13.

Pharmacology and physiopathology of the brain endothelin system: an overview.

Schinelli S.

Curr Med Chem. 2006;13(6):627-38. Review.

PMID:
16529555
14.

Galanin and galanin receptors in human cancers.

Berger A, Santic R, Hauser-Kronberger C, Schilling FH, Kogner P, Ratschek M, Gamper A, Jones N, Sperl W, Kofler B.

Neuropeptides. 2005 Jun;39(3):353-9. Epub 2005 Jan 28. Review.

PMID:
15944034
15.

Does growth hormone drive breast and other cancers?

Waters MJ, Barclay JL.

Endocrinology. 2007 Oct;148(10):4533-5. Review. No abstract available.

PMID:
17876033

Supplemental Content

Support Center